Pharmacopsychiatry 2003; 36: 230-234
DOI: 10.1055/s-2003-45135
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Lithium Augmentation in Treatment-Resistant Depression: Clinical Evidence, Serotonergic and Endocrine Mechanisms

T. Bschor1 , U. Lewitzka1 , J. Sasse2 , M. Adli2 , U. Köberle2 , M. Bauer2
  • 1Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany
  • 2Department of Psychiatry and Psychotherapy, Charité - University Medicine Berlin, Campus Charité-Mitte (CCM), Berlin, Germany
Further Information

Publication History

Publication Date:
15 December 2003 (online)

For now more than 50 years, lithium has been the gold standard for the pharmacologic treatment of bipolar disorder. However, its utility is not restricted to acute mania and prophylactic treatment of bipolar disorder. A relatively new indication for its use is the addition to an antidepressant in the acute treatment phase of unipolar major depression. To date, this treatment approach called lithium augmentation is the best-documented approach in the treatment of refractory depression. In international treatment guidelines and algorithms, lithium augmentation is considered a first-line treatment strategy for patients with a major depressive episode who do not adequately respond to standard antidepressant treatment. In a recent double-blind, placebo-controlled trial, lithium augmentation has demonstrated to also be effective in the continuation treatment phase to prevent early relapses. From animal studies there is robust evidence that lithium augmentation increases serotonin (5-HT) neurotransmission, possibly by a synergistic action of lithium and the antidepressant on brain 5-HT pathways. In contrast to the established decline of HPA system activity during treatment with tricyclic antidepressants, neuroendocrine studies on the effects of lithium augmentation on the HPA system showed an unexpected and marked increase in the ACTH and cortisol response in the combined DEX/CRH test. Here we review new data on the efficacy and mechanism of action of lithium augmentation.

References

  • 1 Adli M, Berghöfer A, Linden M, Helmchen H, Müller-Oerlinghausen B, Mackert A, Stamm T, Bauer M. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study.  J Clin Psychiatry. 2002;  63 782-790
  • 2 Adli M, Bschor T, Canata B, Döpfmer S, Bauer M. Lithium in the treatment of acute depression [Article in German].  Fortschr Neurol Psychiatr. 1998;  66 435-441
  • 3 Álvarez E, Pérez-Solá V, Pérez-Blanco J, Queraltó J M, Torrubia R, Noguera R. Predicting outcome of lithium added to antidepressants in resistant depression.  J Affect Disord. 1997;  42 179-186
  • 4 Amsterdam J D, Winokur A, Abelman E, Lucki I, Rickels K. Cosyntropin (ACTH alpha 1 - 24) stimulation test in depressed patients and healthy subjects.  Am J Psychiatry. 1983;  140 907-909
  • 5 Barden N, Reul J M, Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?.  Trends Neurosci. 1995;  18 6-11
  • 6 Bauer M, Adli M, Baethge C, Berghöfer A, Sasse J, Bschor T. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms.  Can J Psychiat. 2003;  48 440-446
  • 7 Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle A, Müller Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression.  Am J Psychiatry. 2000;  157 1429-1435
  • 8 Bauer M, Forsthoff A, Baethge C, Adli M, Berghöfer A, Döpfmer S, Bschor T. Lithium augmentation therapy in refractory depression - Update 2002.  Eur Arch Psychiatry Clin Neurosci. 2003;  253 132-139
  • 9 Bauer M, Döpfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies.  J Clin Psychopharmacol. 1999;  19 427-434
  • 10 Bauer M, Whybrow P C, Angst J, Versiani M, Möller H J. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder.  World J Biol Psychiatr. 2002;  3 5-43
  • 11 Bauer M. The combined use of lithium and SSRIs.  J Serotonin Res. 1995;  2 69-76
  • 12 Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier-Perey M. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation.  J Clin Psychopharmacol. 1996;  16 307-314
  • 13 Blier P, Montigny de C. Short-term lithium administration enhances serotonergic neurotransmission: electrophysiological evidence in the rat CNS.  Eur J Pharmacol. 1985;  133 66-77
  • 14 Browne M, Lapierre Y D, Hrdina P D, Horn E. Lithium as an adjunct in the treatment of major depression.  Int Clin Psychopharmacol. 1990;  5 103-110
  • 15 Bschor T, Adli M, Baethge C, Eichmann U, Ising M, Uhr M, Modell S, Künzel H, Müller-Oerlinghausen B, Bauer M. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression.  Neuropsychopharmacol. 2002;  27 470-478
  • 16 Bschor T, Baethge C, Adli M, Eichmann U, Ising M, Uhr M, Modell S, Künzel H, Müller-Oerlinghausen B, Bauer M. Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder.  J Psychiat Res. 2003;  37 135-143
  • 17 Bschor T, Baethge C, Adli M, Eichmann U, Ising M, Uhr M, Müller-Oerlinghausen B, Bauer M. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression.  Depress Anxiety. 2003;  17 43-48
  • 18 Bschor T, Berghöfer A, Ströhle A, Kunz D, Adli M, Müller-Oerlinghausen B, Bauer M. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression.  J Clin Psychopharmacol. 2002;  22 427-430
  • 19 Bschor T, Canata B, Müller-Oerlinghausen B, Bauer M. Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression.  J Affect Disorders. 2001;  64 261-265
  • 20 Chaput Y, Montigny de C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat.  Neuropsychopharmacology. 1991;  5 219-229
  • 21 Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji H K. Enhancement of hippocampal neurogenesis by lithium.  J Neurochem. 2000;  75 1729-1734
  • 22 Cowen P J, McCance S L, Ware C J, Cohen P R, Chalmers J S, Julier D L. Lithium in tricyclic-resistant depression. Correlation of increased brain 5-HT function with clinical outcome.  Br J Psychiatry. 1991;  159 341-346
  • 23 Crismon M L, Trivedi M, Pigott T A, Rush A J, Hirschfeld R M, Kahn D A, DeBattista C, Nelson J C, Nierenberg A A, Sackeim H A, Thase M E. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.  J Clin Psychiatry. 1999;  60 142-156
  • 24 Dinan T G. Psychoneuroendocrinology of mood disorders.  Curr Opin Psychiatry. 2001;  14 51-55
  • 25 Dinan T G. Neuroendocrinology of mood disorders. Curr Opin Psychiatry 1997 10: 84-87
  • 26 Fieve R R, Peselow E D. Lithium: clinical applications. In Burrows GD, editor Psychiatry Series. Amsterdam; Elsevier 1994: pp. 277-321
  • 27 Gibbs D M, Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood.  Brain Res. 1983;  280 176-179
  • 28 Heninger G R, Charney D S, Sternberg D E. Lithium carbonate augmentation of antidepressant treatment.  Arch Gen Psychiatry. 1983;  40 1335-1342
  • 29 Heuser I JE, Schweiger U, Gotthardt U, Schmider J, Lammers C H, Dettling M, Yassouridis A, Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects.  Am J Psychiatry. 1996;  153 93-99
  • 30 Holsboer F, Lauer Ch J, Schreiber W, Krieg J C. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders.  Neuroendocrinology. 1995;  62 340-347
  • 31 Holsboer F. The corticosteroid receptor hypothesis of depression.  Neuropsychopharmacol. 2000;  23 477-501
  • 32 Huang X, Wu D Y, Chen G, Manji H, Chen D F. Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism.  Invest Ophthalmol Vis Sci. 2003;  44 347-354
  • 33 Jacobs B L, Azmitia E C. Structure and function of the brain serotonin system.  Physiol Rev. 1992;  72 165-229
  • 34 Joffe R T, Levitt A J, Bagby R M, MacDonald C, Singer W. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders.  Br J Psychiatry. 1993;  163 574-578
  • 35 Joffe R T, Singer W, Levitt A J, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.  Arch Gen Psychiatry. 1993;  50 387-393
  • 36 Kantor D, McNevin S, Leichner P, Harper D, Krenn M. The benefit of lithium carbonate adjunct in refractory depression - fact or fiction?.  Can J Psychiatry. 1986;  31 416-418
  • 37 Katona C LE, Abou-Saleh M T, Harrison D A, Nairac B A, Edwards D RL, Lock T, Burns R A, Robertson M M. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.  Br J Psychiatry. 1995;  166 80-86
  • 38 Lenox R H, Hahn C G. Overview of the mechanism of action of lithium in the brain: fifty-year update.  J Clin Psychiatry. 2000;  61 (suppl 9) 5-15
  • 39 Maes M, Meltzer H Y. The serotonin hypotheses of major depression. In Bloom FE, Kupfer DJ, editors Psychopharmacology: The Fourth Generation of Progess. New York; Raven Press 1995: 933-944
  • 40 Manji H K, Lenox R H. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness.  Biol Psychiatry. 1999;  46 1328-1351
  • 41 Manji H K, Moore G J, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers.  Br J Psychiatry. 2001;  178 (suppl 41) 107-119
  • 42 Manji H K, Quiroz J A, Sporn J, Payne J L, Denicoff K, A Gray N, Zarate CA J r, Charney D S. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.  Biol Psychiatry. 2003;  53 707-742
  • 43 McCance-Katz E, Price L H, Charney D S, Heninger G R. Serotonergic function during lithium augmentation of refractory depression.  Psychopharmacology. 1992;  108 93-97
  • 44 Montigny de C, Aghajanian G K. Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin.  Science. 1978;  202 1303-1306
  • 45 Montigny de C, Cournoyer G, Morisette R. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antideoressant drugs and lithium on the serotonin system.  Arch Gen Psychiatry. 1983;  40 1327-1334
  • 46 Montigny de C, Grunberg F, Mayer A, Deschenes J P. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders.  Br J Psychiatry. 1981;  138 252-256
  • 47 Montigny de C. Lithium addition in refractory depression. In Nolen WA, Zohar J, Roose SP, Amsterdam JD, editors Refractory Depression: Current Strategies and Future Directions. London; John Wiley & Sons, Ltd 1994: 47-57
  • 48 Montigny de C. Lithium addition in treatment-resistant depression.  Int Clin Psychopharmacol. 1994;  9 (suppl 2) 31-35
  • 49 Montigny de C. Lithium addition in treatment-resistant depression: evidence for the involvement of the serotonin system. In Racagni G, Brunello N, Fukuda T, editors Biological Psychiatry. Volume 1 Amsterdam; Elsevier Science Publishers B.V. 1991: 243-244
  • 50 Müller-Oerlinghausen B. Lithium long-term treatment - does it act via serotonin?.  Pharmacopsychiatry. 1985;  18 214-217
  • 51 Nelson J C, Mazure C M. Lithium augmentation in psychotic depression refractory to combined drug treatment.  Am J Psychiatry. 1986;  143 363-366
  • 52 Nelson J C. Overcoming treatment resistance in depression.  J Clin Psychiatry. 1998;  59 (suppl 16) 13-19
  • 53 Nemeroff C B. Augmentation strategies in patients with refractory depression.  Depress Anxiety. 1996;  4 169-181
  • 54 Okamoto Y, Motohasi N, Hayakawa H, Muraoka M, Yamawaki S. Addition of lithium to chronic antidepressant treatment potentiates presynaptic serotonergic function without changes in serotonergic receptors in the rat cerebral cortex.  Neuropsychobiology. 1996;  33 17-20
  • 55 Phiel C J, Wilson C A, Lee V M, Klein P S. GSK-3alpha regulates production of Alzheimer"s disease amyloid-beta peptides.  Nature. 2003;  423 435-439
  • 56 Platman S R, Fieve R R. Lithium carbonate and plasma cortisol response in the affective disorders.  Arch Gen Psychiatry. 1968;  18 591-594
  • 57 Platman S R, Hilton J G, Koss M C, Kelly W G. Production of cortisol in patients with manic-depressive psychosis treated with lithium carbonate.  Dis Nerv Syst. 1971;  32 542-544
  • 58 Price L H, Carpenter L L, Rasmussen S A. Drug combination strategies. In Amsterdam JD, Hornig M, Nierenberg AA, editors Treatment-resistant mood disorders. Cambridge; University Press 2001: 194-222
  • 59 Price L H, Charney D S, Delgado P L, Goodman W K, Krystal J H, Woods S W, Heninger G R. Clinical studies of 5-HT function using i. v. L-tryptophan.  Prog Neuropsychopharmacol Biol Psychiatry. 1990;  14 459-472
  • 60 Price L H, Charney D S, Delgado P L, Heninger G R. Lithium and serotonin function: implications for the serotonin hypothesis of depression.  Psychopharmacology (Berl). 1990;  100 3-12
  • 61 Price L H, Charney D S, Henninger G R. Variability of response to lithium augmentation in refractory depression.  Am J Psychiatry. 1986;  143 1387-1392
  • 62 Reisine T, Zatz M. Interactions among lithium, calcium, diacylglycerides, and phorbolesters in the regulation of adrenocorticotropin hormone release from AtT-20 cells.  J Neurochem. 1987;  49 884-889
  • 63 Rouillon F, Gorwood P. The use of lithium to augment antidepressant medication.  J Clin Psychiatry. 1998;  59 (suppl 5) 32-39
  • 64 Rybakowski J, Matkowski K. Adding lithium to antidepressant therapy: factors related to therapeutic potentiation.  Eur Neuropsychopharmacol. 1992;  2 161-165
  • 65 Schatzberg A F, Garlow S J, Nemeroff C B. Molecular and cellular mechanisms in depression. In Davis KL, Charney D, Coyle JT, Nemeroff C, editors Neuropsychopharmacology: The Fifth Generation of Progress. American College of Neuropsychopharmacology. Philadelphia; Lippincott Williams & Wilkins 2002: 1039-1050
  • 66 Schöpf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study.  Pharmacopsychiatry. 1989;  22 183-187
  • 67 Shelton R C. Treatment options for refractory depression.  J Clin Psychiatry. 1999;  60 (suppl 4) 57-61
  • 68 Souza F G, Goodwin G M. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis.  Br J Psychiatry. 1991;  158 666-675
  • 69 Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses.  Br J Psychiatry. 1993;  162 634-640
  • 70 Sugawara M, Hashimoto K, Hattori T, Takao T, Suemaru S, Ota Z. Effects of lithium on the hypothalamo-pituitary-adrenal axis.  Endocrinol Jpn. 1988;  35 655-663
  • 71 Thase M E, Rush A J. Treatment-resistant depression. In Bloom FE, Kupfer DJ, editors Psychopharmacology: The fourth generation of progress. New York; Raven Press 1995: 1081-1097
  • 72 Torres G, Horowitz J M, Laflamme N, Rivest S. Fluoxetine induces the transcription of genes encoding c-fos, corticotropin-releasing factor and its type 1 receptor in rat brain.  Neuroscience. 1998;  87 463-477
  • 73 Wegener G, Bandpey Z, Heiberg I L, Mork A, Rosenberg R. Increased extracellular serotonin level in rat hippocampus induced by chronic citalopram is augmented by subchronic lithium: neurochemical and behavioural studies in the rat.  Psychopharmacology (Berl). 2003;  166 188-194
  • 74 Zatz M, Reisine T D. Lithium induces corticotropin secretion and desensitization in cultured anterior pituitary cells.  Proc Natl Acad Sci USA. 1985;  82 1286-1290
  • 75 Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors.  Pharmacopsychiatry. 2001;  34 119-127
  • 76 Zusky P M, Biederman J, Rosenbaum J F, Manschreck T C, Gross C C, Weilberg J B, Gastfriend D R. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study.  J Clin Psychopharmacol. 1988;  8 120-124

Michael Bauer, M.D., Ph. D.

Department of Psychiatry and Psychotherapy

Charité - University Medicine Berlin

Campus Charité-Mitte (CCM)

Schumannstr. 20/21

10117 Berlin

Germany

Phone: +49-30- 450 51 70 70

Fax: +49-30-450-51 79 62

Email: michael.bauer@charite.de

    >